Form D · Biotechnology
Xagenic Inc.
Toronto, A6 · CIK 0001594154
Offering snapshot reported Dec 12, 2013 · SEC filing
- Reported sold
- $9.59M Offering amount: $21.3M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 26, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 12, 2013 | Initial | $9,588,224 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-207891
Source: Form D, filed Dec 12, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ihor Boszko | Executive |
| Bruce A. Cohen | Director, Executive |
| Jack D. Graham | Executive |
| Erik Holmlin, Ph.D., M.B.A. | Director |
| Shana Kelley, Ph.D. | Director, Executive |
| Yuri Kuzyk | Executive |
| Shermaine Tilley, Ph.D., M.B.A. | Director |
| Jesse Treu, Ph.D. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
55 York Street, Suite 1600
Toronto, A6, M5J 1R7
Toronto, A6, M5J 1R7